EMEA-000619-PIP02-10 - paediatric investigation plan

Pralatrexate
PIPHuman

Key facts

Active Substance
Pralatrexate
Therapeutic area
Oncology
Decision number
P/270/2010
PIP number
EMEA-000619-PIP02-10
Pharmaceutical form(s)
  • Solution for injection
  • Solution for infusion
Condition(s) / indication(s)
  • Treatment of Hodgkin lymphoma
  • Treatment of lymphoblastic non-Hodgkin lymphoma
  • Treatment of mature B-cell non-Hodgkin lymphoma
  • Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Route(s) of administration
  • Intravenous use
  • Intrathecal use
Contact for public enquiries

Allos Therapeutics Limited

pedinfo@allos.com
United States
Phone: +1 3034266262
Fax: +1 3034129160

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page